Substance P-like immunoreactivity in human cerebrospinal fluid.
In a study to elucidate molecular mechanisms in pain, substance P-like immunoreactivity (SP-LI) was measured in lumbar CSF from 75 patients with lower back pain. Two samples--one before and one after lidocaine treatment--were obtained from each patient, and total SP-LI was measured in unfractionated (no HPLC) samples. SP-LI data were separated into three categories: placebo responders, pharmacological responders, and pharmacological non-responders. A significant difference was observed between the total SP-LI measurement of first and second samples of pharmacological non-responders. Distribution of SP-LI immunoreactive molecular species in two CSF patient samples (no ODS) was analyzed with a combination of reversed phase (RP) HPLC and RIA. Immunoreactivity in collected HPLC fractions was measured at calibrated retention times of synthetic SP-sulfoxide (SP-O), SP, and SP. Qualitative and quantitative differences in those HPLC-RIA metabolic profiles were observed within and between those two patients' samples. These data indicate that the type and amount of SP metabolism and SP precursor-processing differs in CSF between these two representative patients and within the short amount of time elapsed between acquiring these two samples.
Higa
T
T
Charles B. Stout Neuroscience Mass Spectrometry Laboratory, College of Medicine, University of Tennessee, Memphis.
Wood
G
G
Desiderio
D M
DM
D001416:Back Pain / Q000134:cerebrospinal fluid*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D008161:Lumbosacral Region; D011863:Radioimmunoassay; D013373:Substance P / Q000134:cerebrospinal fluid*
D013373:Substance P